These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 16462711

  • 21. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 22. Combined iron chelation therapy.
    Galanello R, Agus A, Campus S, Danjou F, Giardina PJ, Grady RW.
    Ann N Y Acad Sci; 2010 Aug; 1202():79-86. PubMed ID: 20712777
    [Abstract] [Full Text] [Related]

  • 23. Combined chelation therapy with deferiprone and desferrioxamine in iron overloaded beta-thalassemia patients.
    Athanassiou-Metaxa M, Kousi A, Hatzipantelis ES, Tsatra I, Ikonomou M, Perifanis V, Tsantali H.
    Haematologica; 2004 Apr; 89(4):ELT07. PubMed ID: 15075120
    [No Abstract] [Full Text] [Related]

  • 24. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2006 Apr; 30(2):239-49. PubMed ID: 16798649
    [Abstract] [Full Text] [Related]

  • 25. Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients.
    Hatzipantelis ES, Karasmanis K, Perifanis V, Vlachaki E, Tziomalos K, Economou M.
    Hemoglobin; 2014 Apr; 38(2):111-4. PubMed ID: 24351163
    [Abstract] [Full Text] [Related]

  • 26. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
    Karakukcu C, Karakukcu M, Unal E, Patiroglu T, Ozdemir MA, Torun YA, Tang PH.
    Hemoglobin; 2012 Apr; 36(3):219-29. PubMed ID: 22483337
    [Abstract] [Full Text] [Related]

  • 27. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S, Pathare AV.
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [Abstract] [Full Text] [Related]

  • 28. Pancreatic iron and glucose dysregulation in thalassemia major.
    Noetzli LJ, Mittelman SD, Watanabe RM, Coates TD, Wood JC.
    Am J Hematol; 2012 Feb; 87(2):155-60. PubMed ID: 22120775
    [Abstract] [Full Text] [Related]

  • 29. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
    Kontoghiorghes GJ.
    Hemoglobin; 2009 Feb; 33(5):332-8. PubMed ID: 19814679
    [Abstract] [Full Text] [Related]

  • 30. A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
    Ha SY, Chik KW, Ling SC, Lee AC, Luk CW, Lam CW, Ng IO, Chan GC.
    Hemoglobin; 2006 Feb; 30(2):263-74. PubMed ID: 16798652
    [Abstract] [Full Text] [Related]

  • 31. Liver iron and serum ferritin levels are misleading for estimating cardiac, pancreatic, splenic and total body iron load in thalassemia patients: factors influencing the heterogenic distribution of excess storage iron in organs as identified by MRI T2*.
    Kolnagou A, Natsiopoulos K, Kleanthous M, Ioannou A, Kontoghiorghes GJ.
    Toxicol Mech Methods; 2013 Jan; 23(1):48-56. PubMed ID: 22943064
    [Abstract] [Full Text] [Related]

  • 32. Pilot study on the "quality of life" as reflected by psychosocial adjustment of children with thalassemia major undergoing iron-chelating treatment in western Taiwan.
    Kuo HT, Tsai MY, Peng CT, Wu KH.
    Hemoglobin; 2006 Jan; 30(2):291-9. PubMed ID: 16798654
    [Abstract] [Full Text] [Related]

  • 33. Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with beta-thalassaemia major: comparison between different chelation regimens.
    Christoforidis A, Haritandi A, Tsatra I, Tsitourides I, Karyda S, Athanassiou-Metaxa M.
    Eur J Haematol; 2007 Jan; 78(1):52-7. PubMed ID: 17042760
    [Abstract] [Full Text] [Related]

  • 34. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M, Printza N, Teli A, Tzimouli V, Tsatra I, Papachristou F, Athanassiou-Metaxa M.
    Acta Haematol; 2010 Jan; 123(3):148-52. PubMed ID: 20185899
    [Abstract] [Full Text] [Related]

  • 35. Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
    Tsiapras D, Fragatou S, Farmaki K, Kyrzopoulos S, Paraskevaidis I, Voudris V, Kremastinos D.
    Hemoglobin; 2010 Jun; 34(3):210-20. PubMed ID: 20524811
    [Abstract] [Full Text] [Related]

  • 36. Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.
    Drakonaki EE, Maris TG, Maragaki S, Klironomos V, Papadakis A, Karantanas AH.
    Hemoglobin; 2010 Jun; 34(1):95-106. PubMed ID: 20113293
    [Abstract] [Full Text] [Related]

  • 37. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload.
    Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, Lordan N, Ishak K, Proskorovsky I.
    Adv Ther; 2008 Aug; 25(8):725-42. PubMed ID: 18704280
    [Abstract] [Full Text] [Related]

  • 38. Maintenance of normal range body iron store levels for up to 4.5 years in thalassemia major patients using deferiprone monotherapy.
    Kolnagou A, Kontoghiorghes GJ.
    Hemoglobin; 2010 Jun; 34(3):204-9. PubMed ID: 20524810
    [Abstract] [Full Text] [Related]

  • 39. Evolution of glucose intolerance and diabetes in transfused patients with thalassemia.
    Kattamis C, Ladis V, Tsoussis D, Kaloumenou I, Theodoridis C.
    Pediatr Endocrinol Rev; 2004 Dec; 2 Suppl 2():267-71. PubMed ID: 16462709
    [Abstract] [Full Text] [Related]

  • 40. Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study.
    Ricchi P, Ammirabile M, Spasiano A, Costantini S, Cinque P, Di Matola T, Pagano L, Prossomariti L.
    Eur J Haematol; 2010 Jul; 85(1):36-42. PubMed ID: 20331740
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.